Business context and reporting period
This is Inotek Pharmaceuticals Corporation’s unaudited Form 10-Q for the quarter ended March 31, 2017. The request metadata identifies Rocket Pharmaceuticals, Inc., but the filing itself is for Inotek; verify the issuer before relying on this summary. Inotek was a clinical-stage eye-disease company with no approved products and no product revenue.
Financial results and liquidity
| Metric | Q1 2017 | Q1 2016 / comparison |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $7.1 million | $7.6 million |
| General and administrative expense | $2.9 million | $2.5 million |
| Operating loss | $10.0 million | $10.1 million |
| Net loss | $10.7 million | $10.1 million |
| Net loss per share | $0.40 | $0.38 |
| Cash used in operating activities | $11.6 million | $9.0 million |
At March 31, 2017, cash and cash equivalents were $25.3 million and short-term investments were $89.4 million, totaling $114.7 million; the company reported total current assets of $116.6 million and current liabilities of $5.3 million. Stockholders’ equity was $63.3 million. No gross margin was reported because the company had no revenue.
Outstanding 2021 Convertible Notes had $52.0 million principal and a $49.1 million net carrying value. They bear 5.75% stated interest (7.3% effective rate), with principal due August 1, 2021; cash interest payments were approximately $1.5 million semiannually. Management estimated funding sufficient into 2019, but stated additional financing would be needed.
Material changes versus the prior comparable period
- Net loss increased $0.6 million year over year, primarily reflecting $0.9 million interest expense on the 2021 notes; operating loss improved by $0.2 million.
- R&D expense declined $0.5 million. Lower spending after completion of the MATrX-1 Phase 3 trial was partly offset by spending on the FDC Phase 2 trial and increased preclinical and personnel costs.
- Operating cash use rose $2.6 million year over year. Cash and cash equivalents fell $4.5 million from year-end, while short-term investments declined $7.2 million.
Outlook, risks and unusual items
- MATrX-1, a pivotal Phase 3 trabodenoson monotherapy trial, failed its primary endpoint: it did not show a statistically significant difference from placebo at every specified time point. The company cited an unexpectedly large placebo response and a treatment-by-site interaction at four of 55 sites. Some secondary outcomes were positive, and the filing reports no significant safety or tolerability events.
- The company was reassessing the clinical and regulatory path for trabodenoson monotherapy. It expected results from its approximately 200-patient trabodenoson/latanoprost fixed-dose-combination Phase 2 trial in July 2017; active enrollment was completed in April.
- Management did not expect aggregate R&D expense to increase in 2017 over 2016, but expected continuing losses and substantial future funding needs. Funding estimates are uncertain and depend on clinical progress, costs, and access to capital.
- A putative shareholder class action filed in January 2017 alleges securities-law violations related to statements about MATrX-1. The company said it intended to defend the case; potential damages were unspecified.
- Other key risks include clinical and regulatory failure, dependence on third-party manufacturers and clinical vendors, future dilution or financing constraints, and the notes’ repayment and conversion provisions. The filing reports disclosure controls were effective at a reasonable-assurance level and no material change in internal control during the quarter.
Important facts for investors to verify
- Confirm the issuer: this filing names Inotek Pharmaceuticals Corporation, not Rocket Pharmaceuticals, Inc.
- Review subsequent disclosures on the FDC Phase 2 results and the company’s decision on further trabodenoson monotherapy development.
- Assess cash burn against the stated runway into 2019, including clinical costs, semiannual note interest, and financing availability.
- Check developments in the securities litigation and any related financial exposure.
- Review the 2021 notes’ $52.0 million principal, conversion terms, and potential shareholder dilution.